Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to introduce a national plan to tackle shortages of pancreatic enzyme replacement therapy.

The Department has been working with suppliers to address current supply issues with Creon, which is a brand of pancreatic enzyme replacement therapy (PERT) used by patients with conditions such as cystic fibrosis and certain cancers including pancreatic cancer. The supply issues with Creon are impacting countries throughout Europe and have been caused by limited availability of raw ingredients and manufacturing capacity constraints to produce volumes needed to meet demand. These issues have resulted in knock-on supply disruptions of alternative PERT medications. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.

The supplier of Creon has advised that they expect to have regular supplies released each month going forward, and are working to increase the quantities released. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules which pharmacists can use to restrict supply to one month at a time to ensure more patients have access to it whilst stock is limited.

We have worked closely with colleagues in NHS England to issue comprehensive guidance to healthcare professionals about these supply issues, and encourage sharing of local solutions. The guidance provides advice on how to manage patients whilst there is disruption to supply and is being kept under review, with updates made as necessary.